五、参考文献 [1] FDA. Guidance for Industry: Considering Whether an
FDARegulated Product Involves the Application of Nanotechnology.2014. [2] FDA. Guidance for Industry: Drug Products,
Including Biological Products, that Contain Nanomaterials（draft）.
2017. [3] FDA. Nanotechnology: A report of the U.S. Food and
Drug Administration Nanotechnology Task Force，2007. [4] FDA. Guidance for Industry: Liposome Drug Products
Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and
Bioavailability; and Labeling Documentation. 2002. [5] US National Institutes of Health Campus. Report on
the 2016 Global Summit on Regulatory Science (GSRS16): Nanotechnology Standards
and Applications [EB/OL]. 2016. [6] EMA. Surface coatings: general issues for
consideration regarding parenteral
administration of coated nanomedicine products. 2013. [7] EMA. Data requirements for intravenous iron-based
nanocolloidal products developed with reference to an innovator medicinal
product. 2015. [8] EMA. Data requirements for intravenous liposomal
products developed with reference to an innovator liposomal product. 2013. [9] EMA. Development of block-copolymer-micelle
medicinal products. 2014. [10] MHLW. Reflection paper on nucleic acids
(siRNA)-loaded nanotechnology-based drug products. 2016. [11] MHLW. Guideline for the Development of Liposome
Drug Products. 2016. [12] Nanomedicine Characterisation Laboratory. Assay
Cascade. http://www.euncl.eu/about-us/assay-cascade. [13] NMPA.化学药品注射剂仿制药（特殊注射剂）质量和疗效一致性评价技术要求. 2020. [14] NMPA.盐酸多柔比星脂质体注射液仿制药研究技术指导原则（试行）. 2020. [15] Taha MS, Padmakumar S, Singh A, et al. Critical
quality attributes in the development of therapeutic nanomedicines toward
clinical translation. Drug delivery and translational research. 2020, 10 (3):
766-790. [16] Tyner KM, Zheng N, Choi S, et al. How Has CDER
Prepared for the Nano Revolution? A Review of Risk Assessment, Regulatory
Research, and Guidance Activities. The AAPS journal. 2017, 19 (4): 1071-1083. [17] Crist RM, Grossman JH, Patri AK, et al. Common
pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology
Characterization Laboratory. Integrative Biology. 2013, 5 (1): 66-73. [18] Rawal M, Singh A, Amiji MM. Quality-by-Design
Concepts to Improve Nanotechnology-Based Drug Development. Pharm Res. 2019, 36
(11): 153. [19] Pallotta A, Boudier A, Creusot B, et al. Quality
control of gold nanoparticles as pharmaceutical ingredients. Int J Pharm. 2019,
569: 118583. [20] Ansar SM, Mudalige T. Direct and simultaneous
determination of intra-liposomal and external sulfate in liposomal doxorubicin
formulations by capillary electrophoresis/inductively coupled plasma-tandem mass spectrometry (CE/ICP-MS/MS). Int J
Pharm. 2019; 561: 283-288. [21] Coty J-B, Vauthier C. Characterization of
nanomedicines: A reflection on a field under construction needed for clinical
translation success. J Control Release. 2018, 275: 254-268. [22] Varenne F, Hillaireau H, Bataille J, et al.
Application of validated protocols to characterize size and zeta potential of
dispersed materials using light scattering methods. Colloid Surface A, 2019,
560, 418-425. [23] D'Souza S. A review of in vitro drug release test
methods for nano-sized dosage forms. Adv. Pharm., 2014, 2014 (2), 1-12. [24] Fontana F, Figueiredo P, Zhang P, et al. Production
of pure drug nanocrystals and nano co-crystals by confinement methods. Adv.
Drug Deliv. Rev. 2018, 131, 3-21.20 六、附录
|
